Stockreport

Aclaris Therapeutics Announces Positive Results From Phase 1 Single and Multiple Ascending Dose Trial of ATI-450, an Investigational Oral MK2 Inhibitor

Aclaris Therapeutics, Inc.  (ACRS) 
Last aclaris therapeutics, inc. earnings: 2/25 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: aclaristx.com
PDF •  Oral small molecule showed marked inhibition of TNFa, IL1ß, IL8, and IL6•  Preliminary data support progression to Phase 2a Proof of Concept Trials in Immuno-Inflamma [Read more]